Therapeutic drug monitoring of vancomycin in adult patients: From guideline recommendations to practical clinical use
Abstract
Vancomycin is a cornerstone agent in the treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and other penicillin-resistant gram-positive bacteria. Due to its narrow therapeutic window and substantial interindividual pharmacokinetic variability, individualized dosing is crucial. Therapeutic drug monitoring (TDM) enables dose adjustments based on patient-specific pharmacokinetic parameters and measured serum concentrations, thereby enhancing therapeutic efficacy while minimizing adverse effects, such as nephrotoxicity. Variations in renal function, underlying comorbidities, and concomitant use of nephrotoxic medications are important clinical determinants that increase the need for TDM. Additionally, careful monitoring is required due to infusion-related reactions, acute kidney injury, and hematologic toxicities associated with vancomycin therapy. Current guidelines recommend shifting from trough concentration–based monitoring to evaluation of the 24-hour area under the concentration–time curve/minimum inhibitory concentration (AUC24/MIC) ratio, particularly in the management of severe MRSA infections. However, because many centers lack the infrastructure required for routine AUC-based monitoring, trough-based TDM remains widely used and clinically relevant. In this narrative review, we synthesize current guideline recommendations and established reference sources in infectious diseases and clinical pharmacology to provide a comprehensive overview of the scientific principles, practical methods, target pharmacokinetic/pharmacodynamic thresholds, and real-world challenges associated with vancomycin TDM in adult patients. This work aims to support the standardization of TDM practices and to contribute to improving the safety and effectiveness of vancomycin use in clinical settings within our country.
Keywords
Ethical Statement
References
- 1. Murray BE, Arias CA, Nannini EC. Glycopeptides (Vancomycin and Teikoplanin) and Lipopeptides (Televancin, Oritavancin, and Dalbavancin). In: Blaser MJ, Cohen JI, Holland SM, et al, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 10th ed. Elsevier. Philadelphia 2025. p. 393-404.
- 2. Zamoner W, Prado IRS, Balbi AL, Ponce D. Vancomycin dosing, monitoring and toxicity: Critical review of the clinical practice. Clin Exp Pharmacol Physiol. 2019;46(4):292-301.
- 3. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2020;71(6):1361-4.
- 4. Matsumoto K, Oda K, Shoji K, et al. Clinical practice guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing: A consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Pharmaceutics. 2022;14(3):489.
- 5. He N, Su S, Ye Z, et al. Evidence-based guideline for therapeutic drug monitoring of vancomycin: 2020 update by the division of therapeutic drug monitoring, Chinese Pharmacological Society. Clin Infect Dis. 2020;71(Suppl 4):363-S371.
- 6. Stewart JJ, Jorgensen SC, Dresser L, et al. A Canadian perspective on the revised 2020 ASHP-IDSA-PIDS-SIDP guidelines for vancomycin AUC-based therapeutic drug monitoring for serious MRSA infections. J Assoc Med Microbiol Infect Dis Can. 2021;6(1):3-9.
- 7. Reuter SE, Stocker SL, Alffenaar JC, et al. Optimal practice for vancomycin therapeutic drug monitoring: position statement from the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2022;44(1):121-32.
- 8. Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4:5.
Details
Primary Language
English
Subjects
Infectious Diseases, Clinical Sciences (Other)
Journal Section
Review
Authors
Eda Kübra Sel
0000-0002-6966-2016
Türkiye
Vildan Avkan Oğuz
0000-0001-7648-7730
Türkiye
Ayse Gelal
*
Türkiye
Early Pub Date
April 29, 2026
Publication Date
April 29, 2026
Submission Date
November 26, 2025
Acceptance Date
April 10, 2026
Published in Issue
Year 2026 Volume: 40 Number: 2